Drug Discovery Investment Firms

RaiseHunt lists 1,313 Drug Discovery investment firms.

1,297 of the 1,313 firms list at least one portfolio company, 10,339 known investments between them.

4,815 people working at them have a profile here, each with their role at the firm and whether an email address is on file.

The largest concentrations are in New York, San Francisco and London.

Most list Seed and Series A among their stages.

Every firm page shows whether an email address is on file, and the named contacts at that firm. The addresses themselves, along with AI matching and outreach, are in the RaiseHunt app.

Yes. The directory and every firm page are free to read. Matching your own startup against them requires an account.

No. A focus area is a signal of interest, not a restriction. Firms usually list several, and the useful question is whether the existing portfolio looks like the kind of company you are building.

An angel invests their own money and can decide alone, which usually makes the process shorter. A firm invests money it raised from other people, so it answers to those backers and normally runs a longer diligence process before it commits. Founders often raise from angels first and bring in a firm once there is more to show.

A named partner or principal, not a general company address. Investment decisions sit with individual people, and a message that lands in a shared inbox usually stops there. Each fund page here lists the people we hold a profile for, with their role at the firm.

More than the description on its website. The companies a firm has already backed show the stage it really invests at, the kinds of business model it understands, and whether it has funded anything close to what you are building. Read the portfolio before you read the pitch page.

Often, though not far outside. Sector tags describe where a firm concentrates rather than a rule it follows, and companies that sit between two categories get funded all the time. The stronger signal is whether the firm has backed a business with a similar shape, whatever label it carried.

Far more than feels comfortable. Response rates on cold outreach are low even when the fit is good, so a short list of perfect names tends to stall. Build a long list, sort it by how well each firm matches what you are building, and work down it in batches rather than sending everything at once.